المؤلفون: Lièvre, Astrid, Merlin, Jean-Louis, Sabourin, Jean-Christophe, Artru, Pascal, Tong, Sabine, Libert, Lucie, Audhuy, François, Gicquel, Corinne, Moureau-Zabotto, Laurence, Ossendza, Roch-Anicet, Laurent-Puig, Pierre, Ducreux, Michel

المساهمون: Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL), UNICANCER, Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Merck Sharp and Dohme (Merck & Co. Inc), Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Département d'Hépato-gastro-entérologie Chalons-en-Champagne, Hôpital de Châlons-en-Champagne, Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Oncologie digestive, Département de médecine oncologique Gustave Roussy, Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), This study was sponsored by Merck Santé SAS, Lyon, France, anaffiliate of Merck KGaA, Darmstadt, Germany. The management ofthe study was provided by Merck Santé. The management, monitor-ing, data management and the statistical analyses were performedby, AXONAL-BIOSTATEM, Nanterre, France. The sponsor partici-pated in the design of the study, had oversight on the conduct of thestudy, and participated in interpretation of data and the decisionto publish the results. The corresponding author had full access toall of the data and the final responsibility to submit for publication.

المصدر: ISSN: 1590-8658 ; Digestive and Liver Disease ; https://univ-rennes.hal.science/hal-01778377Test ; Digestive and Liver Disease, 2018, 50 (5), pp.507-512. ⟨10.1016/j.dld.2017.12.029⟩.

مصطلحات موضوعية: RAS, KRAS mutations, Colorectal cancer, Genotyping, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29396127; hal-01778377; https://univ-rennes.hal.science/hal-01778377Test; https://univ-rennes.hal.science/hal-01778377/documentTest; https://univ-rennes.hal.science/hal-01778377/file/Li%C3%A8vre%20et%20al_RAS%20mutation%20testing.pdfTest; PUBMED: 29396127

الإتاحة: https://doi.org/10.1016/j.dld.2017.12.029Test
https://univ-rennes.hal.science/hal-01778377Test
https://univ-rennes.hal.science/hal-01778377/documentTest
https://univ-rennes.hal.science/hal-01778377/file/Li%C3%A8vre%20et%20al_RAS%20mutation%20testing.pdfTest

المؤلفون: Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Troncone, Giancarlo, Dal Mas, Antonella, Coletti, Gino, Frébourg, Thierry, Sabourin, Jean-Christophe, Tosi, Mario, Ficorella, Corrado, Ricevuto, Enrico

المساهمون: Medical Oncology, Università degli Studi dell'Aquila = University of L'Aquila (UNIVAQ)-S. Salvatore Hospital, Department of Experimental Medicine, Università degli Studi dell'Aquila = University of L'Aquila (UNIVAQ), laboratoire de Génétique Somatique des Tumeurs, Hôpital Charles Nicolle Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Department of Biomorphologic and Functional Sciences, University of Naples Federico II = Università degli studi di Napoli Federico II, Pathology Department, S. Salvatore Hospital, Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anatomie et Cytologie Pathologique CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)

المصدر: ISSN: 1741-7015.

مصطلحات موضوعية: disease extension, intensive regimen, KRAS mutations, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23136868; inserm-00764322; https://inserm.hal.science/inserm-00764322Test; https://inserm.hal.science/inserm-00764322/documentTest; https://inserm.hal.science/inserm-00764322/file/1741-7015-10-135.pdfTest; PUBMED: 23136868

الإتاحة: https://doi.org/10.1186/1741-7015-10-135Test
https://inserm.hal.science/inserm-00764322Test
https://inserm.hal.science/inserm-00764322/documentTest
https://inserm.hal.science/inserm-00764322/file/1741-7015-10-135.pdfTest